[{"id":"06c95d25-232d-4edf-bad2-62ebafe8d024","acronym":"","url":"https://clinicaltrials.gov/study/NCT04474470","created_at":"2021-01-18T21:29:42.332Z","updated_at":"2024-07-02T16:35:04.621Z","phase":"Phase 1/2","brief_title":"A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer","source_id_and_acronym":"NCT04474470","lead_sponsor":"TyrNovo Ltd.","biomarkers":" KRAS • BRAF","pipe":" | ","alterations":" KRAS wild-type • RAS wild-type • RAS wild-type + BRAF wild-type","tags":["KRAS • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • RAS wild-type • RAS wild-type + BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • NT219"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 09/03/2020","start_date":" 09/03/2020","primary_txt":" Primary completion: 05/08/2024","primary_completion_date":" 05/08/2024","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2024-05-09"},{"id":"c059badf-8a2b-4247-bace-32ba3408645c","acronym":"","url":"https://clinicaltrials.gov/study/NCT03317119","created_at":"2021-01-18T16:22:52.836Z","updated_at":"2024-07-02T16:35:11.068Z","phase":"Phase 1","brief_title":"Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery","source_id_and_acronym":"NCT03317119","lead_sponsor":"City of Hope Medical Center","biomarkers":" BRAF • PIK3CA • PTEN","pipe":" | ","alterations":" BRAF mutation • PIK3CA mutation • BRAF wild-type • RAS mutation • RAS wild-type • RAS wild-type + BRAF wild-type • PIK3CA mutation + PTEN mutation","tags":["BRAF • PIK3CA • PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • PIK3CA mutation • BRAF wild-type • RAS mutation • RAS wild-type • RAS wild-type + BRAF wild-type • PIK3CA mutation + PTEN mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Lonsurf (trifluridine/tipiracil)"],"overall_status":"Completed","enrollment":" Enrollment 26","initiation":"Initiation: 04/11/2018","start_date":" 04/11/2018","primary_txt":" Primary completion: 07/14/2023","primary_completion_date":" 07/14/2023","study_txt":" Completion: 07/14/2023","study_completion_date":" 07/14/2023","last_update_posted":"2024-04-08"},{"id":"ae83589e-a2ba-488d-8198-d989445aa1f3","acronym":"CAPFOL","url":"https://clinicaltrials.gov/study/NCT05022030","created_at":"2021-08-26T13:53:09.688Z","updated_at":"2024-07-02T16:35:15.787Z","phase":"Phase 2","brief_title":"First-line mCapOX+Cetuximab vs. mFOLFOX6+Cetuximab for Metastatic Left-sided CRC With Wild-type RAS/BRAF Genes","source_id_and_acronym":"NCT05022030 - CAPFOL","lead_sponsor":"West China Hospital","biomarkers":" BRAF","pipe":" | ","alterations":" RAS wild-type • RAS wild-type + BRAF wild-type","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS wild-type • RAS wild-type + BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • 5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 07/21/2021","start_date":" 07/21/2021","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2024-03-07"},{"id":"bfd133ba-4207-42a9-a0dd-8e750a9eae6b","acronym":"HERCKER-01","url":"https://clinicaltrials.gov/study/NCT05985707","created_at":"2023-08-14T16:10:12.961Z","updated_at":"2024-07-02T16:35:39.614Z","phase":"Phase 2","brief_title":"KN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary Carcinoma","source_id_and_acronym":"NCT05985707 - HERCKER-01","lead_sponsor":"Peking University Cancer Hospital \u0026 Institute","biomarkers":" HER-2 • KRAS • BRAF","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification • RAS wild-type • RAS wild-type + BRAF wild-type","tags":["HER-2 • KRAS • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification • RAS wild-type • RAS wild-type + BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • oxaliplatin • erfonrilimab (KN046) • anbenitamab (KN026)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 08/15/2023","start_date":" 08/15/2023","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2023-08-21"},{"id":"70c4de0d-0e45-409f-9fc7-2477495a0d1b","acronym":"","url":"https://clinicaltrials.gov/study/NCT00819780","created_at":"2021-01-18T03:06:57.763Z","updated_at":"2024-07-02T16:35:59.568Z","phase":"Phase 2","brief_title":"PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors","source_id_and_acronym":"NCT00819780","lead_sponsor":"Amgen","biomarkers":" KRAS • BRAF • RAS","pipe":" | ","alterations":" KRAS wild-type • BRAF wild-type • RAS wild-type • RAS wild-type + BRAF wild-type","tags":["KRAS • BRAF • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • BRAF wild-type • RAS wild-type • RAS wild-type + BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • 5-fluorouracil • Vectibix (panitumumab) • oxaliplatin • leucovorin calcium"],"overall_status":"Completed","enrollment":" Enrollment 285","initiation":"Initiation: 04/24/2009","start_date":" 04/24/2009","primary_txt":" Primary completion: 05/30/2012","primary_completion_date":" 05/30/2012","study_txt":" Completion: 07/07/2016","study_completion_date":" 07/07/2016","last_update_posted":"2022-12-06"},{"id":"7c15d7b4-8f3a-418b-8d82-c907323200dc","acronym":"IMPROVE","url":"https://clinicaltrials.gov/study/NCT04425239","created_at":"2021-01-18T21:19:04.657Z","updated_at":"2024-07-02T16:36:13.796Z","phase":"Phase 2","brief_title":"Intermittent or Continuous Panitumumab Plus FOLFIRI for RAS/B-RAF Wild-type Metastatic Colorectal Cancer","source_id_and_acronym":"NCT04425239 - IMPROVE","lead_sponsor":"National Cancer Institute, Naples","biomarkers":" BRAF","pipe":" | ","alterations":" RAS wild-type • RAS wild-type + BRAF wild-type","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS wild-type • RAS wild-type + BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • Vectibix (panitumumab) • irinotecan • leucovorin calcium"],"overall_status":"Completed","enrollment":" Enrollment 151","initiation":"Initiation: 05/21/2018","start_date":" 05/21/2018","primary_txt":" Primary completion: 07/02/2021","primary_completion_date":" 07/02/2021","study_txt":" Completion: 04/03/2022","study_completion_date":" 04/03/2022","last_update_posted":"2022-04-07"}]